Michael Munley to Prognosis
This is a "connection" page, showing publications Michael Munley has written about Prognosis.
Connection Strength
0.098
-
Soike MH, McTyre ER, Hughes RT, Farris M, Cramer CK, LeCompte MC, Lanier CM, Ruiz J, Su J, Watabe K, Bourland JD, Munley MT, O'Neill S, Laxton AW, Tatter SB, Chan MD. Initial brain metastasis velocity: does the rate at which cancers first seed the brain affect outcomes? J Neurooncol. 2018 Sep; 139(2):461-467.
Score: 0.030
-
Lanier CM, McTyre E, LeCompte M, Cramer CK, Hughes R, Watabe K, Lo HW, O'Neill S, Munley MT, Laxton AW, Tatter SB, Ruiz J, Chan MD. The number of prior lines of systemic therapy as a prognostic factor for patients with brain metastases treated with stereotactic radiosurgery: Results of a large single institution retrospective analysis. Clin Neurol Neurosurg. 2018 02; 165:24-28.
Score: 0.029
-
Kilburn JM, Lester SC, Lucas JT, Soike MH, Blackstock AW, Kearns WT, Hinson WH, Miller AA, Petty WJ, Munley MT, Urbanic JJ. Management of mediastinal relapse after treatment with stereotactic body radiotherapy or accelerated hypofractionated radiotherapy for stage I/II non-small-cell lung cancer. J Thorac Oncol. 2014 Apr; 9(4):572-6.
Score: 0.023
-
Socinski MA, Blackstock AW, Bogart JA, Wang X, Munley M, Rosenman J, Gu L, Masters GA, Ungaro P, Sleeper A, Green M, Miller AA, Vokes EE. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol. 2008 May 20; 26(15):2457-63.
Score: 0.015